Remove 2007 Remove Prescription Remove Sales
article thumbnail

UK approves prescription-only melatonin drug for childhood ADHD

Pharmaceutical Technology

Melatonin has a prescription-only status and is strictly regulated in the UK, making this the first time it has been approved for use in this indication. Colonis then sent a corrective letter to the recipients, but a Prescription Medicines Code of Practice Authority panel pointed out that it didn’t specify this was required by the MHRA.

article thumbnail

The Ripple Effect: How Pharmaceutical Advertisements Impact the Industry and Beyond

Pharma Marketing Network

These advertisements are designed to educate and inform consumers about the benefits and risks of prescription drugs, but they can also influence patient behavior in ways that may not always be beneficial. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. References: 1. Knopf Doubleday Publishing Group.

article thumbnail

Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug

pharmaphorum

The substance patent expired in 2007. ” “Given the importance of this issue to patients, payors (including the federal government), and prescription-drug competition, this court should grant review,” it adds. The post Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug appeared first on.

article thumbnail

THEPM360TRAILBLAZER AWARD WINNER – Lifetime Achievement Award – Adam Schechter, CEO and Chairman, Labcorp

PM360

Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. focused leadership roles spanning sales, marketing, and managed markets, as well as business and product development. His extensive experience at Merck also included global and U.S.-focused

Ethics 59
article thumbnail

Beating the Big C

Pharmaceutical Technology

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler. So what’s driving the growth?